Evidence check: VDR in the context of Wechseljahre

The Vitamin D Receptor (VDR) mediates the actions of vitamin D, which is crucial for bone metabolism, calcium balance, and immune regulation. During menopause, declining estrogen accelerates bone loss, increasing osteoporosis risk. VDR gene variants (e.g., FokI, BsmI, TaqI) have been associated with differences in vitamin D sensitivity and, in some studies, with bone mineral density and fracture risk in postmenopausal women. However, the evidence is largely mechanistic and based on observational or GWAS data, not on robust clinical trials that prove personalized supplementation based on VDR genotype improves menopause outcomes. Consumer DNA tests can report these variants, but their clinical utility for managing menopause symptoms (hot flashes, mood changes) remains unclear. Measuring serum 25-hydroxyvitamin D and following general supplementation guidelines is more evidence-based than relying solely on genetic data. Safety note: Do not self-prescribe high-dose vitamin D without lab confirmation.